Amgen opens new biomanufacturing facility in Ohio, US
February 27, 2024Manufacturing and Production Amgen, Biomanufacturing, Manufacturing Facility, Ohio, Pharmacy, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest …
Roche shares data from phase 3 trial of Xolair as allergy treatment
February 26, 2024Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
February 26, 2024Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
February 23, 2024Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
BioAscent opens new protein production facility
February 22, 2024Manufacturing and Production BioAscent, Pharmacy, facility, protein production
BioAscent has announced that it has opened its new state-of-the-art protein production facility in an event chaired by Professor Michael …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
February 21, 2024Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
February 21, 2024Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment
February 20, 2024Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA
argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
Freenome raises $254m funding for early cancer detection platform
February 16, 2024Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …
Domainex opens new Biology Centre of Excellence in Cambridge, UK
February 14, 2024Business Services Pharmacy, domainex, facility
Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
February 14, 2024Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
DelSiTech and Tolmar announce global license and development agreement
February 13, 2024Medical Communications DelSiTech, Pharmacy, Tolmar, collaboration
DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous …
J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
February 12, 2024Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
